Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow
Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...
Healio1d
Dupilumab, tezepelumab lead biologic initiations for severe asthma
Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...
Sanofi: Qfitlia Approval A Bright Spot As Landscape Darkens For European Pharma
Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.
Healio4d
Patients with severe asthma need fewer steroid bursts with tezepelumab-ekko
Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization ...
Regeneron Pharmaceuticals, Inc. (REGN): Among Blue Chip Stocks to Invest in at 52-Week Lows
We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...